ExpreS2ion Biotech (EXPRS2) investor relations material

Key scientific and clinical developments

• Developing a novel therapeutic vaccine (ES2B-C001) targeting HER2-positive breast cancer, addressing high relapse rates and unmet needs, especially in younger women.

• Vaccine induces a broad polyclonal immune response by targeting all four HER2 epitopes, offering advantages over monoclonal antibody therapies.

• Preclinical studies show broad immune response, tumor growth suppression, and tumor-free survival in mice; first-in-human phase I trial initiated in Austria.

• Protocol amendment allows enrollment at multiple centers and inclusion of patients on standard of care; initial immune response observed in first dosed patient.

• Data safety monitoring board meeting scheduled before year-end to evaluate early patient data and advance dose escalation.

Market and competitive landscape

• Addressing a EUR 27 billion oncology market growing at 7% annually, with current HER2 therapies generating over EUR 8 billion in sales.

• Potential for ES2B-C001 to achieve blockbuster status with projected sales exceeding EUR 5 billion per year.

• Inspired by major industry deals, such as AstraZeneca's $7 billion acquisition of Enhertu rights.

• Unique approach with a first-in-class, broad polyclonal response positions the therapy as a differentiated competitor.

• Therapy can be combined with standard of care, enhancing its market potential and partnership opportunities.

Pipeline, partnerships, and platform

• Lead project ES2B-C001 is fully controlled; additional pipeline assets in infectious diseases (malaria, influenza, Nipah virus) supported by grants.

• Recent licensing deal with Serum Institute of India for malaria projects; ExpreS2 platform proven in phase III COVID-19 vaccine trials.

• Leadership team has extensive experience advancing assets from preclinical to phase II and beyond.